Related Experiment Video
Updated: Jun 16, 2026
08:56
Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
Overcoming the obstacles in the pharma/biotech industry: 2009 update.
Ann I Graul1, Laura Revel, Montserrat Tell
1Editorial Department, Thomson Reuters, Barcelona, Spain. ann.graul@thomsonreuters.com
Drug News & Perspectives
|February 16, 2010
Summary
The biopharmaceutical industry faced significant challenges in 2009 due to economic recession, patent expirations, and declining innovation. Traditional strategies are insufficient, suggesting a need for a new research and development model.
Area of Science:
- Biopharmaceutical industry
- Economic challenges
- Research and Development (R&D) models
Background:
- The research-based biopharmaceutical industry encountered numerous obstacles in 2009.
- These challenges were exacerbated by the global economic recession.
- Persistent issues include generic competition, patent expirations, and concerns about innovation.
Purpose of the Study:
- To analyze the impact of the 2009 economic recession on the biopharmaceutical industry.
- To evaluate the effectiveness of traditional strategies employed by companies.
- To explore the necessity for novel R&D models.
Main Methods:
- Analysis of industry trends and challenges in 2009.
- Review of common corporate strategies such as mergers, acquisitions, and licensing.
- Conceptual examination of the limitations of existing R&D frameworks.
Main Results:
- The economic recession intensified pre-existing industry challenges.
- Companies resorted to cost-cutting measures and pipeline-filling strategies.
- Traditional strategies may no longer be adequate to overcome industry limitations.
Conclusions:
- The biopharmaceutical industry's current R&D model faces limitations.
- Existing strategies are insufficient to address the complex challenges.
- A paradigm shift towards entirely new R&D models is potentially required.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...